Who Paid My Doc
Gary Denny
Addiction Medicine Tulsa, OK Doctor of Osteopathy
NPI 1558393637 CMS profile 115446
5310 E 31St St Fl 11 Ste 1102, Tulsa, OK 74135
General payments
$5,892
Research payments
$0
Ownership & investment interest
$0
Through program year 2019, Gary Denny of Tulsa, OK is reported in the CMS Open Payments database as having received $5,892 across 13 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 91st percentile of Addiction Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2019 | General | $5,892 | 13 |
Beside peers
- Gary Denny
- Addiction Medicine median
- Middle half of Addiction Medicine
- National median
In program year 2025, general payments to Gary Denny were reported at $0. Among 183 Addiction Medicine profiles paid that year, the median was $124 and the middle half received between $43 and $384.
Show as a table
| Year | Gary Denny | Addiction Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $5,892 | $115 | $34–$328 | $163 |
| 2020 | $0 | $64 | $22–$259 | $114 |
| 2021 | $0 | $97 | $25–$267 | $132 |
| 2022 | $0 | $70 | $25–$255 | $149 |
| 2023 | $0 | $105 | $29–$270 | $160 |
| 2024 | $0 | $122 | $39–$378 | $164 |
| 2025 | $0 | $124 | $43–$384 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
362
Drug cost
$29,141
Branded share of claims
49.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl | Brand | 153 | $16,184 | |
| Zubsolv Buprenorphine Hcl/Naloxone Hcl | Brand | 13 | $9,562 | |
| Buprenorphine Hcl | Generic | 65 | $1,939 | |
| Trazodone Hcl | Generic | 21 | $559 | |
| Eszopiclone | Generic | 14 | $250 | |
| Quetiapine Fumarate | Generic | 18 | $221 | |
| Amitriptyline Hcl | Generic | 16 | $190 | |
| Buspirone Hcl | Generic | 12 | $141 | |
| Sertraline Hcl | Generic | 24 | $57 | |
| Propranolol Hcl | Generic | 13 | $32 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Records
13 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Addiction Medicine in Oklahoma
Related records
Addiction Medicine in Oklahoma
Practitioners in the same specialty and state, ranked by reported value.
All Addiction Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Oklahoma
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.